Our capabilities

Addex has developed unique capabilities that have allowed to industrialize the discovery of allosteric modulators.

The allosteric modulator discovery platform has enabled Addex to generate a rich pipeline of programs, all 100% owned by Addex, except the licensed programs. The extent of our pipeline, from molecules targeting selectively subtypes of large families of GPCRs to molecules targeting selectively receptor tyrosine kinase subtypes, illustrate the power of the unique and proprietary technologies discovered and used at Addex.